HIV Self-Testing AfRica (STAR) Malawi: General Population V2

A cluster randomised trial of providing HIV self-testing kits through community-based distribution agents

Malawi Investigators

Dr Nicola Desmond [1,3] (Principal Investigator)
Professor Liz Corbett [1,2,3]
Sarah Gibson [7]
Pitchaya Indravudh [1]
Wezzie Lora [1]
Phillip Mkandawire [8]
Chiwawa Nkhoma [8]

Global Investigators

Dr Helen Ayles [6]
Dr Rachel Baggaley [9]
Dr Virginia Bond [6]
Professor Frances Cowan [4,5]
Dr Katherine Fielding [2]
Dr Karin Hatzhold [7]
Dr Rein Houben [2]
Cheryl Johnson [9]
Professor Graham Medley [2]
Dr Melissa Neuman [2]
Professor Rosanna Peeling [2]
Dr Miriam Taegtmeyer [3]
Dr Fern Terris-Prestholt [2]
Amy Power [7]
Professor Helen Weiss [2]
Dr Richard White [2]

Collaborating Institutions

[1] Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Malawi
[2] London School of Hygiene & Tropical Medicine, United Kingdom
[3] Liverpool School of Tropical Medicine, United Kingdom
[4] University College London, United Kingdom
[5] CeSSHAR: Centre for Sexual Health and HIV/AIDS Research, Zimbabwe
[6] ZAMBART: Zambia AIDS Related Tuberculosis Project, Zambia
[7] PSI: Population Services International, United States
[8] PSI: Population Services International, Malawi
[9] World Health Organization, Switzerland

Table of Contents

Abbreviations

ANC	Antenatal Care
ART	Antiretroviral Therapy
CBDAs	Community-Based Distribution Agents
CBO	Community Based Organisation
CD4	Cluster of Differentiation 4
COMREC	College of Medicine Research Ethics Committee
DALY	Disability-Adjusted Life Years
DBS	Dried Blood Spot
DCE	Discrete Choice Experiments
DHO	District Health Office
DHS	Demographic and Health Surveys
ELISA	Enzyme-Linked Immunosorbent Assay
FSW	Female Sex Workers
FBO	Faith-Based Organisation
FGD	Focus Group Discussion
GBV	Gender-Based Violence
GPS	Global Positioning System
HIV	Human Immunodeficiency Virus
HIVOFT	HIV Oral Fluid Tests
HIVRDT	HIV Rapid Diagnostic Tests
HIVST	HIV Self-Testing
HTC	HIV Testing and Counselling
ID	Identification
IDI	In-Depth Interview
IEC	Information, Education and Communication
IFU	Instructions-for-Use
KII	Key Informant Interview
Km	Kilometres
LSHTM	London School of Hygiene and Tropical Medicine
LSTM	Liverpool School of Tropical Medicine
M&E	Monitoring and Evaluation
MLW	Malawi Wellcome Trust Clinical Research Programme
MoH	Ministry of Health
MSM	Men who have Sex with Men
NGO	Non-Governmental Organization
PLHIV	People Living with HIV
PSI	Population Services International
SCQ	Self-Completed Questionnaire
SES	Socio-Economic Status
SOP	Standard Operating Procedures

STAR	Self-Testing Africa
TAG	Technical Advisory Group
TB	Tuberculosis
UCL	University College London
US	United States
USD	US Dollar
VCT	Voluntary Counselling and Testing
VMMC	Voluntary Medical Male Circumcision
WHO	World Health Organization

1. Executive summary

1.1 Research problem

In Malawi, adult HIV prevalence remains high, with pronounced social and economic inequity in HIV testing and linkage to onward services. Self-testing for HIV (HIVST) is becoming an established option for providing highly accurate results when used by lay clients. However, more research is needed to establish the potential role of HIVST in rural Africa, where coverage of HTC services is especially low. This project aims to investigate feasibility, affordability as well as the health and social impact of introducing HIVST to rural communities through existing community-based volunteer services.

1.2 Research description

The HIV STAR Malawi General Population (HIV STAR Malawi GP) study consists of a cluster-randomised trial investigating the effects of introducing HIVST to the remit of volunteers providing reproductive health services to villages in up to 5 Southern Region Districts. This research protocol is nested into the UNITAID/PSI HIV Self-Testing Africa (HIV STAR) project, which is funded to provide 34,068 episodes of HIVST in Malawi during 2016/17 with potential extension to 2018/19.

The trial population will be the catchment population (~62,500 adults) of 20 Rural Primary health clinics that have a) ART services and b) support the activities of reproductive health community-based distribution agents (CBDAs). CBDAs are lay volunteers trained and supervised by PSI to socially market reproductive health products in the rural areas.

1.3 Research aims and objectives

Broadly, to investigate the incremental costs and health benefits of adding HIVST to the remit of existing cadres of community volunteers in the general population in Malawi.

Specific objects are to:

1. Validate the use of the OraQuick HIVST product in rural settings, establish preferences and social harms reporting systems, and conduct baseline surveys.
2. Carry out a pragmatic cluster-randomised trial with ART clinics and their catchment populations, including CBDAs, as the unit of randomisation.
3. Evaluate the impact of adding HIVST into the remit of VMMC mobilisers on demand for VMMC
4. Establish the expected costs and benefits of introducing HIVST to Malawi through economic and mathematical modelling.
5. Conduct interviews with policy-makers to prepare for national scale-up of HIVST and support the market introduction of quality-assured HIVST products.

1.4 Methodology

A population-based CRT with associated mixed methods sub-studies. The intervention will be delivered through CBDAs, trained by PSI to provide HIVST in their rural villages. 20 ART Clinics and their catchment populations will be randomised to either HIVST or standard of care (SOC) arms. The ~200 CBDAs in the HIVST arm will be trained to provide HIVST (OraQuick ADVANCE HIV I/II test kits, packaged for self-use) along with reproductive health products. CBDAs will provide brief pre-test information and a self-referral form with all kits to facilitated linkage into HIV care and prevention services. Post-test advice will be provided for all who confide positive HIVST results.

Outcomes will be captured at 12 months through:

1. Household level surveys (~5,000 adults) at baseline and after 12 months of intervention .These will include questions on recent HIV testing through any modality (**Primary Outcome)**.
2. ART clinic records to investigate whether or not population-level demand for ART has increased (**Secondary Outcome)**.

A second stage randomisation of HIVST CBDAs will further explore the role of home-based HIV care assessment for encouraging disclose of positive HIVST results and ART initiation. This is an implementation research study, and no biological specimens will be required for research other than for pilot accuracy evaluation.
The study will be preceded by pilot studies to test the ability to interpret pictorial instructions and accurately use and interpret HIVST kits (packaged with instructions in Chichewa). The trial will be accompanied by economic evaluations. Interviews with key informants will be used to explore the policy and regulatory landscape for HIVST. Tools developed for the main study will be evaluated in other community volunteer cadres, notably voluntary medical male circumcision mobilisers.

1.5 Research findings and dissemination

Early evidence in Malawi points to substantial willingness to self-test and the potential of HIVST products to provide affordable community-based HTC and improve linkages to HIV services. The results of this research will be used to guide the introduction of self-testing into community-based HTC models and the formation of national and international policies around HIVST. Results will be disseminated to the Ministry of Health (MoH) HIV Unit, College of Medicine Research and Ethics Committee (COMREC) and UNITAID. Findings will also be distributed internationally to global health policy makers, nationally to the Malawian government, and regionally to District and Council Health Offices.

2. Background

Malawi has a high HIV prevalence, with an estimated 10.2% of adults living with HIV. Of those who are HIV positive, 46% are on Antiretroviral Therapy (ART) (UNAIDS 2014). In key populations, HIV prevalence is substantially higher than in the general population, with estimated prevalence of 21.4% among Men who have Sex with Men (MSM) and 70.7% among Female Sex Workers (FSWs) (Wirtz, et al. 2014) (Baral, et al. 2009).

Major factors driving new HIV infections in Malawi include lack of knowledge on partner HIV status in serodiscordant relationships, high rates of transactional sex, and low uptake of HIV prevention services including consistent condom use and Voluntary Medical Male Circumcision (VMMC) (UNAIDS 2014). According to the 2010 Demographic and Health Survey (DHS), 9.7% of male respondents had paid for sex at least once, with low condom use (60.7%) during transactional sex (National Statistical Office and ICF Macro 2011). Uptake of VMMC in Malawi was estimated as 2% in December 2012 (UNAIDS 2014).

Reaching the Joint United Nations Programme on AIDS (UNAIDS) 90-90-90 targets (90% of all HIV-positive individuals aware of their status, of whom 90% are retained in ART programmes, of whom 90% have viral load suppression) will require substantial scale-up of HIV testing services with new approaches that more effectively reach marginalised populations who are not well served by current approaches. Notable gaps in HIV Testing and Counselling (HTC) coverage exist for men, adolescents (age 16 to 19 years), rural Malawians and the poorest members of society (National Statistical Office and ICF Macro 2011).

A further challenge is that linkage into HIV treatment and VMMC services following HTC remains suboptimal. In Blantyre, only 50.7% of newly diagnosed People Living with HIV (PLHIV) at routine facilities had successfully completed eligibility assessments and were retained into care 6 months after testing positive (MacPherson, et al. 2012).

Barriers to HTC and ART initiation include long distance and congestion of health facilities, concerns about lack of confidentiality and privacy, and high out-of-pocket costs (MacPherson, et al. 2012, Morin, et al. 2006, Angotti, et al. 2009). These barriers are particularly significant among certain demographics, including men, young people, impoverished rural residents (Weinreb and Stecklov 2009) and key populations (i.e., SWs, MSM) (Govindasamy, Ford and Kranzer 2012). Therefore, current HTC strategies, which are predicated on clinic-based service delivery, need to be complemented by affordable community-based services that allow better coverage, particularly for key populations and rural populations in Malawi.

Based on previous work in Malawi, proactive and accountable distribution of HIV Self-Testing (HIVST) products offers the promise of providing a safe and accurate form of HIV testing and facilitating acceptable rates of linkage into HIV care.

2.1 HIV self-testing

The development of HIV Rapid Diagnostic Tests (HIVRDT) has enabled highly accurate results from HIVST when carried out by untrained lay clients (Choko, et al. 2015). On a societal level, HIVST requires lower human resource demands and could provide more cost-

effective community-based HTC in comparison to current community-based models (Cambiano, Mavedzenge and Phillips 2014).

HIVST kits are already available for purchase over-the-counter in several countries, including the United States, United Kingdom, and Kenya. However, the availability of quality-assured HIVST products will remain limited in resource-poor settings until the purchase of HIVST kits using donor funds is possible and national HIV programmes have adapted policy and programme documents, including algorithms and training materials, to fully accommodate HIVST (Ministry of Health Kenya 2009).

To be put on approved donor purchase lists, HIVST products need to be suitably low cost and be supported by:

1. Product approval by the World Health Organisation (WHO) Prequalification Department. An application is currently underway for OraQuick ADVANCE Rapid HIV-1/2 Antibody Test – the HIVST product to be used under the HIV STAR Malawi study – and has already received approval from the United States Food and Drug Administration (FDA).
2. WHO guidelines to support the use of HIVST in defined populations, such as rural and urban adults living in high HIV prevalence settings, adolescents, and key populations.

WHO and UNAIDS have already issued Technical Updates that are supportive of HIVST, but the development of full guidelines requires results from implementation research to evaluate the public health risks and benefits from introducing HIVST into a range of settings. Key considerations include user ability to conduct HIVST and interpret results, user ability to cope with and act upon positive HIVST results in the absence of face-to-face counselling, the accuracy of test results particularly among low literacy populations, and the potential for unwanted social harms such as coercive testing and gender-based violence (GBV) (Napierala Mavedzenge and Corbett 2009, Wright and Katz 2006, Pant-Pai and Klein 2008, Frith 2007).

Though evidence to date has been reassuring, more data is needed from implementation studies in representative African populations (Napierala Mavedzenge and Corbett 2009, Wright and Katz 2006, Pant-Pai and Klein 2008, Frith 2007, Gaydos, et al. 2009, Project Masiluleke 2010)

2.2 HIV self-testing in Malawi

Malawi has assumed a leadership position in HIVST research, with the only large-scale implementation project to date. From 2012-2015, a HIVST study was conducted in Blantyre in collaboration with the National HIV department (Choko, et al. 2015) and has produced results that have been highly influential in moving forward international policy regarding HIVST.

Choko, et al. demonstrated that there was high readiness for HIVST, with pronounced user preference for HIVST over facility-based services, and high accuracy of results. Acceptability was even high among men and adolescents, who have been difficult to reach with standard HTC services. Acceptable rates of linkage to confirmatory testing and HIV care services were also obtained through the promotion of HIVST by briefly trained local volunteers and provision of home-based ART eligibility assessments (MacPherson, et al. 2014). This resulted in a significant increase in demand for ART services at population level.

Additionally, national HIV policies and strategic frameworks (e.g., 2016-25 National HIV and AIDS Strategic Plan, 2015-20 HIV Prevention Strategy), have started to mention HIVST, but have yet to include adapted HIV testing algorithms and HTC materials and standard operating procedures and guidelines for how HIVST should complement current HTC models.

2.3 UNITAID/PSI HIV STAR project

The UNITAID/PSI HIV STAR project will conduct HIVST implementation research to generate the evidence base required for WHO guidelines in Malawi, Zambia and Zimbabwe. The project has a dual focus on marginalised sections of the general population (defined by poor coverage of HTC under current strategies) and key populations (i.e., FSWs, MSM).

Collaborators include WHO, Population Services International (PSI), London School of Hygiene and Tropical Medicine (LSHTM), Liverpool School of Tropical Medicine (LSTM), and University College London (UCL).

PSI is responsible for HIVST implementation, while LSHTM, in conjunction with local partners (the Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW) in Malawi) is responsible for implementation research. WHO will lead the development of policy and regulatory guidelines around HIVST.

The funding body for the UNITAID/PSI HIV STAR project is UNITAID, a United Nations organisation housed within WHO that supports the development and optimisation of robust, high-quality and low-cost products specifically intended to meet the diagnostic and pharmaceutical needs of HIV, tuberculosis (TB) and malaria programmes in low-resource countries.

Figure 1. HIV STAR Project Organogram



2.3.1 Overall project goal

The UNITAID/PSI HIV STAR project aims to catalyse the HIVST market regionally by testing innovative interventions and strengthening the evidence base around the effective use of HIVST through formative research and impact evaluation.

2.3.2 Overall project objectives

The primary objective is to increase the uptake of quality-assured HIVST among general and key populations in Malawi, Zambia and Zimbabwe.

The secondary objectives are:

1. *To increase access to quality-assured HIVST among target populations:* This includes directly addressing the availability, adaptability and affordability of HIVST and developing context-specific distribution models to more effectively reach target consumers.
2. *To increase informed demand for quality-assured HIVST:* The project will conduct formative market research to increase product responsiveness to client needs and preferences for HIVST, as well as improve package inserts and other IEC products so that clients are provided with the information they need to effectively use the tests and access relevant post-test services.
3. *To reduce policy barriers to market entry for quality-assured HIVST products:* This means using evidence around preferences and demand for HIVST to estimate the market size and to inform global and national policy and guidelines, thereby helping to create a supportive policy and regulatory environment in which quality products can be introduced.

Figure 2. HIV STAR objectives and activities

Objectives	Implementation Activities	Research Activities	Policy Activities
1. Increase access to quality-assured HIVST among target populations in intervention areas.	• Distribute HIVST kits through CBDAs, social marketing franchises, peer educators, and VMMC mobilisers to target populations.	• Conduct formative research and preparatory work for HIV distribution models. • Pilot and conduct interim evaluations of HIV distribution models.	• Partner with MoH on developing training curriculum and tools for CBDAs and defining acceptable CBDA cadres. • Work with MoH to include HIVST in national algorithms.
2. Increase informed consumer demand for quality-assured HIVST.	• Develop marketing and communication strategy using marketing planning processes. • Strategically design and test branded packaging and inserts.	• Conduct formative market research to better understand barriers and motivators to using HIVRDT for self-testing. • Perform economic and mathematical modelling of HIVST delivery.	• Share findings on user preferences with MoH collaborators.
3. Reduce policy barriers to market entry for quality-assured HIVST products.	• Establish expert HIVST Advisory Board to provide scientific oversight on project implementation and to inform global quality standards and guidelines.	• Provide technical support and assistance for global and national-level policy makers and regulators. • Disseminate findings at key intervals with local, national and international stakeholders.	• Develop normative guidance on HIVST.

2.3.3 Summary of UNITAID/PSI HIV STAR activities

In 2016 and 2017, PSI plans to provide a total of 171,054 HIVST kits to underserved general population adults and key populations in Malawi using multiple distribution channels.

Among the general population, HIV STAR will target rural and peri-urban populations, urban populations, and young men, with corresponding distribution models for each sub-group. The launch of multiple channels for HIVST distribution will help HIV STAR to reach all sub-groups as well as increase the evidence around effective models for HIVST delivery and linkage to HIV prevention and care.

The distribution of HIVST kits to the general population will take place through the following PSI-led mechanisms:

1. *CBDAs* – Community-based distribution agents (CBDA) will distribute HIVST kits, among other health products, to populations in rural and peri-urban areas, which generally have been underserved by HTC services.

2. *Tunza* – Tunza franchise providers, which are contracted by PSI and provide socially marketed products through the private sector, will deliver HIVST kits to urban populations. For this sub-group, lack of privacy and confidentiality often are the biggest barriers to HTC.
3. *VMMC mobilisers* – VMMC mobilisers will offer HIVST kits to men ages 15 to 49, who are the target of VMMC campaigns. A frequently cited barrier to VMMC uptake is the perceived requirement for HTC. Therefore, HIVST among this sub-group has the potential to increase the uptake of this critical HIV prevention service.

MLW-LSHTM will conduct a series of research studies, packaged as *HIV STAR Malawi*, to inform and evaluate PSI HIVST implementation. The HIV STAR Malawi study is then divided into two protocols based on the target population segment:

1. *HIV STAR Malawi General Population (HIV STAR Malawi GP)* – This protocol consists of a cluster randomised trial (CRT) to evaluate HIVST interventions among the general population. The study will also conduct formative research to inform the design of HIVST distribution models.
2. *HIV STAR Malawi Key Populations (HIV STAR Malawi KP)* – MLW-LSHTM will conduct formative research to inform peer-led delivery models among FSWs and MSM. The study will also carry out social harms research to monitor unintended consequences from accessing HIVST.

Figure 3. Breakdown of target populations

Target Populations	Target Number of Self-Tests* Year 1	Year 2	Total	Districts	Distribution models
1. General population					
Rural and peri-urban populations	25,000	96,000	121,000	Blantyre, Mwanza, Machinga, Thyolo	CBDAs
Tunza social franchise clients	3,600	27,000	30,600	Mchinji, Lilongwe, Salima, Dedza, Nkhotakota, Kasungu	Tunza providers
Potential VMMC clients	1,500	4,800	6,300	Blantyre	VMMC mobilisers
2. Key populations					
MSM	540	2,592	3,132	Blantyre, Lilongwe, Mzuzu	MSM peer educators
SSWs	1,728	8,294	10,022	Blantyre, Lilongwe, Mzuzu	FSW peer educators
Total	**32,368**	**138,686**	**171,054**		

*Includes cases of repeat testing with the same individual.

3. Research question, aims, objectives

HIVST research findings have so far have been limited to a single delivery model in urban Blantyre. Findings such as acceptability and accuracy of HIVST may not be generalizable to other target populations, including rural adults, and may also change along with cost and cost-effectiveness when different service delivery models are used.

Here we investigate the uptake, acceptability, safety, population-impact and costs of adding HIVST to the remit of two existing cadres of community volunteers working in Malawi:

1. Rural-based community-based distribution agents (CBDAs) who provide reproductive health and child survival commodities through social marketing in rural areas.
2. VMMC mobilisers who provide information on voluntary male circumcision services.

The main research questions to be addressed are

- Does HIVST provided through multifunctional community volunteers maintain high willingness to self-test, safety, accuracy, and acceptable uptake of post-test services?
- Does adding HIVST to reproductive health CBDA services increase coverage of recent HIV-testing at population-level?
- Does adding HIVST to reproductive health CBDA services increase demand for ART?
- Does the offer of home assessment and HIV care initiation improve linkage into post-test services?
- What are the social effects (benefits and harms) of introducing HIVST through community health
- What are the incremental costs and cost-effectiveness of adding community-based HTC?

3.1 Research objectives

3.1.1 Research objectives

The broad objectives are to investigate the incremental costs and health benefits of adding HIVST to the remit of existing cadres of community volunteers to adults in the general population in Malawi. Ultimately this may contribute to the ability to meet and sustain National 90-90-90 targets as well as informing regional policy and practice.

The specific objectives are to:

1. Evaluate the impact of introducing HIVST into the remit of reproductive health CBDAs, with and without the option of home-assessment and initiation of HIV care, on HIV testing coverage and ART initiation rates.
2. Evaluate the impact of adding HIVST into the remit of VMMC mobilisers on VMMC initiation rates.
3. Establish the expected costs and benefits of introducing HIVST to Malawi.
4. Evaluate preferences for HIVST delivery and linkage to care models.

5. Identify policy and regulatory barriers and enablers to the scale-up of HIVST and actions needed to support the market introduction of quality-assured HIVST product

4. Study design

4.1 Main trial

The main study will be a cluster-randomised trial in up to 5 high HIV prevalence districts (provisionally Blantyre, Machinga, Mwanza, Neno and Thyolo) that already have community-based reproductive health services provided by PSI under funding provided by the German Technical Cooperation Agency (GTZ). This programme supports volunteers to socially-market reproductive and child health products in villages, with products stored and managed by collaborating primary care clinics.

Figure 4. Schematic illustration of Standard of Care and HIVST intervention clusters intervention provided by village-based CBDAs.



Unit of randomisation is the Primary Care + ART Clinic (black cross) and surrounding catchment area villages (large circles with feed-in arrows) to clinic. CBDAs in the HIVST Arm villages will be trained to provide HIVST services as well as reproductive health services (**small solid circles**). CBDAs in the SOC Arm villages will remain with reproductive health services only (**small open circles**). Two separate units of evaluation will be pre-defined before randomisation: one or two evaluation villages that will have baseline-final household surveys, and a wider catchment area including all villages with CBDA activities.

The unit of randomisation will be the **primary care clinic.** The **unit of evaluation** will be defined by **clinic records of adult ART initiations** from villages within the wider CBDA catchment area, and through household survey of **1 to 2 evaluation villages** contained within the catchment population (Figure 5).

The trial will compare **population-level uptake of ART** (as defined by ART clinic records of new initiators listing study villages as their home address) and **coverage of recent HIV testing** (as defined by household surveys) between two arms:

1. **Intervention arm**: Addition of HIVST kits, with brief training and IEC material, to the products carried by PSI-supported reproductive health CBDAs, or
2. **SOC arm**: CBDAs will continue to offer reproductive health services, but without the addition of HIVST kits

Figure 5. Trial timelines



In a **second-stage randomisation arm**, villages included in the HIVST intervention will be further randomised to

1. **Arm 1A: HIVST plus optional home assessment for HIV care.** CBDAs will offer all clients willing to confide their preliminary positive result the option of having their confirmatory testing and initial HIV care assessment (registration card and the first 2 weeks of cotrimoxazole and ART, if eligible) at home, or
2. **Arm 1B: HIVST only:** CBDAs will offer advice and encouragement to all clients to confide a preliminary positive result, in order to allow the OraQuick test to be repeated by the CBDA who will then provide a written referral slip to the nearest ART clinic.

Figure 6. Summary of HIVST CRT arms and second stage randomisation



Home-based assessment from HIV care following HIVST was shown to be effective in urban Blantyre (MacPherson, et al. 2012).

4.2 Sub-Studies

Accompanying substudies, including quantitative, qualitative and economic evaluations, are described in detail below.

4.3 Primary and secondary outcomes

4.3.1 Primary Outcome for main HIVST versus SOC CBDA intervention

The primary outcome is: Comparison between randomisation arms in coverage of recent (within the last 12 months) HIV testing among adult (16 years and above) village residents 12 months after the initiation of the intervention.

A related pre-specified analysis is to compare between randomisation arms the coverage of ever (lifetime) HIV testing among adult (16 years and above) village residents.

These analyses will be based on household surveys carried out in the pre-defined evaluation villages in each randomisation arm.

4.3.2 Secondary Outcome for main HIVST versus SOC CBDA intervention

The secondary outcome is: Comparison between randomisation arms of ART initiation rates for adult (16 yrs or older) cluster residents, during months 1 to 12 of intervention.

This analysis will be based on data extraction from routine ART clinic records. Residential address will be used to identify all new initiations among adults (16 years or older) living within the the wider CBDA catchment area relating to that clinic.

4.3.3 Second stage randomisation: home-based versus facility-based assessment for HIV care

Villages in the HIVST intervention area will be randomised to either **HIVST only,** or to **HIVST plus offer of home assessment and HIV care initiation** (first assessment and first 14 days of HIV care medications) with this additional intervention aimed at facilitating linkage into care.

The **primary outcome** for this second-stage randomisation will be comparison between randomisation arms of number of adult (16 yrs or older) village residents disclosing a positive results to the CBDA during months 1 to 12 of intervention, with a confidential post-test log book used to capture these data.

The **secondary outcome** for this second-stage randomisation will be comparison between randomisation arms of ART initiation rates for adult (16 yrs or older) village residents during months 1 to 12 of intervention, with ART clinic records used for this assessment.

4.4 Study population and timeline

Phase 1 of the study is funded from 1st Sept 2015 to August 2017. A second two-year funding phase has been requested, and will if successful allow continuation of the implementation and research. The decision on Phase 2 funding will be made in April 2017.

The main study population will be adults living in selected evaluation villages located within the 5 Southern Districts that have an existing reproductive CDBA programme (Blantyre, Machinga, Mwanza, Neno and Thyolo).

20 Primary care clinics that are actively participating in PSI-CBDA scheme and have an active ART clinic will be selected, with preference given to sites with evidence of high HIV burden in surrounding villages (based on ANC clinic data).

Selection of 20 to 40 evaluation villages for the purposes of household surveys will be based on distance from the primary care clinic (aiming for sites that are at least 10km away), plus considerations affecting ease of access and follow-up. Ideal villages will have an active CDBA volunteer, an adult population of greater than 250, with no alternative HIV care facility nearby, and with no major access problems during the rainy season. If necessary, 2 villages will be selected from any given primary care clinic catchment area to meet the requirement for 250 adults evaluated.

Additional populations will be included for the purposes of the formative studies, the interviews with policymakers, and the VMMC mobilisers.

1. Formative studies will include initial cognitive interviews with a convenience sample of up to 144 participants attending routine HTC clinics, to establish ability to understand and follow the new instructions for use before moving into the village residents
2. HIVST ICE materials will be piloted for accuracy and acceptability in 2 non-intervention villages within the intervention Districts
3. Policymakers and opinion leaders on HIV testing will be included in key informant interviews aiming to support scale up of HIVST if these evaluation studies are promising
4. Mobile VMMC clinics operate in overlapping districts and sites to the main cluster randomised trial. The initial evaluation of adding HIVST to VMMC mobilisers will be carried out within the catchment area of the study primary care clinics. However, if results are promising then the intervention will be extended to all PSI VMMC clinic sites, which include other districts.

5. Methods

HIVST will use the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test. The kits, which are manufactured by Orasure, contain the HIVOFT kit, stand, buffer solution, IFUs, materials on counselling and linkage to care, and primary and secondary packaging.

A toll-free telephone number will also be provided with the HIVST kit, which can be used to access verbal pre-test information, test instructions, and results-based post-test information. Participants will also be given information on the nearest clinic for confirmatory testing and ART initiation.

The kits will be distributed for free across all of the distribution models. All distributors will receive a training package in HIVST promotion and support that has been developed in consultation with MoH HIV Department.

The study has four main phases:

1. Formative studies
2. Piloting in non-intervention area 2 villages
3. Cluster enumeration in all 20 ART clinics and evaluation villages
4. Intervention and outcome evaluation

5.1 Formative studies and piloting

Formative studies are intended to

- Establish ability to follow HIV implementation the instructions-for-use and confirm high accuracy of supervised HIVST in rural settings
- Inform our understanding of needs through key informant interviews with stakeholders working in HIV policy, product regulation and HIV implementation

5.1.1 Cognitive interviews

Convenience sampling will be used to recruit clients from VCT clinics for the cognitive interviews (PS101A). Eligibility criteria include clients who are 16 years or older, and willing to provide written informed consent for participation in the study. A witnessed thumbprint will be sufficient for those who are unable to read or write. Participants will be purposively selected to ensure a range in location and literacy level.

Four to 12 participants will be recruited for each iteration of the cognitive interviews, with a maximum of 12 iterations of adaptation and trial of the intended IFUs (n = 144). Cognitive interviewing and iterative adaptation will continue until saturation occurs and no further modifications to user materials are made.

5.1.2 Key informant interviews

Approximately 45 participants will be selected purposively through snowball sampling for the KIIs (PS201). MLW-LSHTM, using their professional networks and PSI country staff, will identify appropriate stakeholders. Interviews will be with written informed consent, will use semi-structured questionnaires and will be audiotaped.

5.1.3 Village selection and community mapping

Primary care clinics and evaluation villagers will be selected in consultation with the program lead for PSI's CBDA programme, and in consultation with the relevant District Health Offices, Primary care clinics and the CBDAs themselves.

Once villages have been selected, preliminary mapping exercises will be initiated including demarcation of the village boundaries and location of dwellings with geographical position system (GPS) and a brief household-level questionnaire (name of household head, demographics of household members).

Sensitisation will include village-level meetings, as well as introduction of the project to village health committees, village governance bodies (e.g., traditional councils), community peer groups, and community-based organisations engaged in HIV and other social services. Membership size and gender and age structure of active community peer-groups (church groups, sports, micro-finance etc) will also be listed during sensitisation.

5.1.4 Pilot study of uptake and accuracy

Two villages not included in the main study will be selected from rural Blantyre or Machinga for pilot studies of accuracy and acceptability. From these villages, 200 to 250 participants in total will be recruited from either randomly selected households (n = 150-200) or community peer groups (n = 48) for the accuracy and acceptability studies.

Peer group members

Two peer groups identified during community mapping exercises will be purposively selected from each of the villages to participate in FGDs (PS301) on HIVST. The groups should broadly represent men, women and youth. Written consent will be required by members in order to participate in the FGDs. Should a peer group refuse, another group will be selected to take its place.

Each FGD will consist of 8 to 12 individuals (n = 48). FGDs will cover barriers and motivators to self-testing and linkage to care as well as group-based dynamics around information sharing and HIVST demonstration. The FGDs will also assess background preferences for service delivery and linkage to care approaches and identify the most salient service attributes that drive decision-making.

Randomly selected households

In addition, 150 to 200 adults will be recruited from a random selection of 60 to 80 households (with an estimated 2-5 adults per household) using randomly selected GPS waypoints. All household members aged 16 years or older will be asked for written consent to answer a brief questionnaire (socio demographics, past HIV testing experience, chronic care including ART) and will be offered HIVST followed immediately by confirmatory HTC (PS303A). Parental consent will be taken for 16 and 17-year-olds and witnessed thumbprint for individuals unable to read or write.

Offer of HIVST and exit interviews

Participants who opt to self-test as well as undergo standard HTC will be given a HIVST kit and a test results forms to record their own reading of the results (PS303B). They will then be provided with a demonstration and instructions before carrying out the self-test

procedure in a private room and completing the test results forms. Participants who themselves recognise that they have made a user error or find that their first result is uninterpretable will be given a second test kit to repeat the procedure if they wish to do so.

Following self-testing, trained HTC counsellors will record their own reading of the test kit before completing the standard HTC process (parallel Unigold and Determine finger prick blood) and entering the results of blood-based testing. All patients testing HIV+ve will be referred to HIV care services.

Figure 7. HIV testing flow chart



Specimens will not be stored. However, if discordant test results are obtained, the participant will be asked to consent to providing a dried blood spot sample for subsequent laboratory Enzyme-Linked Immunosorbent Assay (ELISA) and ART drug assay.

Finally, all participants will undergo a brief semi-structured exit interview (PS303C/PS303D) exploring the reasons why a particular HTC option was chosen, asking about their self-testing experience. Feedback will be sought to improve piloted information materials and instructions.

Use of pilot accuracy results

Under the most likely range of scenarios (point estimate of accuracy 95% to 98%), then 200 participants accepting HIVST will be sufficient to exclude (at p = 0.05) an accuracy of below 90%. If the observed accuracy is as high as 98%, then these numbers would be sufficient to exclude an accuracy of below 95% at p = 0.05.

If accuracy is below 90% then the accuracy component of this study will be repeated after IEC supportive materials have been refined.

5.1.5 In-depth interviews

Following the accuracy study, 40 eligible participants will be identified for in-depth interviews (IDIs) according to the categories listed in the purposive sampling framework. An information sheet on the study will be provided to obtain informed, written consent. Researchers will then move on to the next listed household until a sufficient number of participants have been recruited.

Figure 8. Stratified IDI framework

		Village 1		Village 2		Total
		Previous testing	No previous testing	Previous testing	No previous testing	
HIV negative	Aged 16 to 39	2	2	2	2	8
	Aged 40+	2	2	2	2	8
	Aged 16 to 39	2	2	2	2	8
	Aged 40+	2	2	2	2	8
HIV positive		2	2	2	2	8
Total		10	10	10	10	40

The IDI (PS302A/302B) will collect data on perceived barriers and motivators to HTC and linkage to care, as well as HTC preferences. The data will be used to analyse readiness and acceptability of self-testing, user preferences for different self-testing options, and factors influencing HIVST uptake and linkage to onward services in different contexts.

Input will also be obtained for two intended study tools: a component of the baseline household questionnaire that will use pictorial representations of salient attributes for different HTC scenarios, and an illustrated self-completed questionnaire that HIVST participants will be asked to complete during the intervention study.

IDI participants will be presented with the proposed images and self-completed questionnaires and asked what they think they represent. If the pictures are not immediately clear, the concepts will be explained and the images shown again at the end of the IDI to

check for recognition. Over the sequence of the IDIs, the tool will be iteratively adapted until it is suitable for inclusion as a Selection of villages

20 primary care facilities offering ART services across the 5 districts will be included in the intervention. Clinic eligibility will be constrained on a specific set of criteria, including:

- CBDA activity in at least one village within its catchment area.
- Location in a district with relatively high HIV prevalence estimates.
- Well-functioning ART services and operations, as assessed by the Department of HIV and AIDS.

5.2 Cluster enumeration

5.2.1 Definition of the study population

20 primary care clinics offering ART services will be included in the intervention. The broader catchment population required for ART uptake evaluation (10 to 20 villages) will be defined in consultation with the clinic staff and PSI CBDA Project Manager. A catchment area that does not cross District boundaries and does not have major alternative ART providers will be selected if possible.

Following this, one or 2 evaluation villages within the ART clinic catchment area will be selected. Eligibility requirement for the evaluation villages include:

- Location within the catchment area of an eligible ART clinic, with the clinic acting as the most dominant source of ARTs for the village.
- Presence of at least one active PSI CBDA.
- Population of 250 to 500 adults.
- Road access for most/all of the year.
- Sufficient distance and separation from administrative boundaries and other intended evaluation villages to minimise 1) 'contamination' between HIVST and control villages, and 2) missed linkage to events from seeking HIV care at a remote clinic not included in the evaluation.
- Villages delineated by natural boundaries (e.g., rivers, roads, forests, etc.) will be preferentially selected.

5.2.2 Baseline household surveys

All households in the evaluation villages will be visited for enumeration and invited to participate in the baseline household survey (PS401A). Village boundaries will be defined by obtained GPS coordinates.

An appointment will be made to visit the head of household or authorised individual to explain the study. All adults and older adolescents will be asked for verbal consent to participate, with verbal consent from guardians required in the case of adolescents.

As part of the baseline household survey, a household-level questionnaire of household size, age and gender composition, and socioeconomic indicators will be administered. Each adult household member will then be asked for verbal consent to participate in a brief individual questionnaire on demographic characteristics and experience with HIV testing and care.

A random selection of participants will then also be asked for written consent to complete an extended individual questionnaire on sexual behaviour, stigma, and health service utilisation, including costs. A discrete choice module will investigate user preferences for HIV delivery and linkage to care.

One in 4 household survey participants will be randomly allocated to a longer questionnaire (PS401B/PS402A), includes an approach to establishing user preferences by asking participants to make a series of trade-off choices (discrete choice experiment: DCE). Written or witnessed informed consent (or assent with guardian consent in the case of adolescents) will be obtained beforehand. Selection will be determined based on a random number generated by the electronic survey device at the time of the household survey (Choko, et al. 2015).

A post-intervention survey will be conducted with the same evaluation villages 12 months after the start of HIVST services. The post-intervention survey will consist of the household and brief individual questionnaires as well as an additional section on self-testing.

5.3 Randomisation and investigator blinding

Following baseline enumeration, ART clinic-evaluation village pairs will be randomly allocated to the intervention or control arm at a public ceremony using constrained randomisation.

Balls or discs numbered 1-N (where N represents the number of possible randomisation combinations) will be selected from an opaque bag by a stakeholder representative. The selected number will correspond to a pre-specified combination of clinics in Arms A and B.

A second opaque bag containing 2 balls – one for HIVST and one for SOC – will then be used to allocate the arm to the selected combination in a second drawing process.
It will not be possible to blind participants, community workers, or their supervisors to the cluster intervention allocation, but all specimens and forms and data analysis conducted by laboratory, data, and health facility staff will be managed without reference to the intervention arm.

Outcome data will not be analysed by intervention arm until the final data analysis after completion of the trial, with the exception of data analysis by an independent statistician for presentation to the Data Safety Monitoring Board.

5.4 Intervention procedures and process evaluation

5.4.1 Intervention procedures

CBDAs linked to PHC clinics allocated to the intervention arm will be provided with training in HIVST and IEC materials including flipboards, used kits to show clients how to interpret positive, negative and inconclusive results, a cotton bud and vial of water to demonstrate the mouth swabbing and development process, leaflets and a buffer stock of OraQuick ADVANCE HIV I/II test kits, to be stored in a locked container in their own home.

Adult (16 years or older) participants wishing to know their status will be provided with brief pre-test counselling together with the kit, and an envelope containing a self-completed

questionnaire for return of the used test, a telephone hotline number, a self-referral slip for the nearest PHC offering ART services in case of a positive result, and information on how to access VMMC for HIV-negative men. The kit contains instructions for use and results interpretation in Chichewa.

Clients will be encouraged to return their used kits confidentially to the CBDA, either in person or by posting in the sealed envelope into an opaque locked "ballot box" container kept in the counsellor's house. Clients will also be encouraged to seek post-test advice from the CBDA, which can be "generic" (i.e. not results based) or results-based.

Kits will be replaced by the PHC clinic supervisors on presentation of used kits, and following inspection of an HIV test logbook to confirm recording of names and addresses, but not results, of clients. Numbers of used kits, and results on late re-read, will be recorded by the CBDA/PHC supervisor. HIVST logbooks will be kept at the CBDAs home in a locked container.

There are no sharps or hazardous materials.
Couple's testing will be encouraged. In the case of couples wanting to self-test together, both partners will be asked to attend the IEC session, but clients will also be allowed to take up to 2 kits home if the partner cannot attend.

Testing of children (aged 15 years or less) will not be permitted as part of this trial, but can be arranged through special arrangement with the PSI Supervisors.
For CBDAs participating in the **Home-initiation Arm** of the second stage randomisation, additional training will be provided on how to advise the client about the availability of this option, and the need to share a provisionally positive HIVST result in order to access this option.

Once a client requests home assessment, the CBDA will be responsible for arranging a clinical (ART trained nurse) visit to the participant's home or designated meeting point within 3 days to carry out confirmatory HIV testing, WHO staging, CD4 cell count (Alere PIMA CD4), and TB screening. They will also provide 2 weeks of Co-trimoxazole and ART if the participant meets eligibility requirements. Participants will then be provided with a completed ART registration card and follow-up appointment at the ART clinic.

5.4.2 Participant selection, inclusion and exclusion criteria

The inclusion criteria for clients are:

- Age 16 years or above
- Usual residence within a study PHC catchment area
- Able and willing to provide oral consent to HTC

The exclusion criteria for participation in the ACF intervention will be:

- Age 15 years or below
- Usual residence outside of the intervention cluster

5.4.3 VMMC mobilisers and Tunza Network

Using adaptations of the methods developed for the main CDBA trial, training packages, IEC materials, use of returned kits plus SQC for quality control, and social harms reporting

will be used to evaluate the potential role for HIVST delivered through VMMC mobilisers and the Tunza Network.

PSI-VMMC mobilisers will be trained to offer HIVST kits to men ages 15 to 49, who are the target of VMMC campaigns. Research evaluation will be limited to safety reporting aspects and analysis of the effect of introducing this method through comparison of before-after time trends in demand for VMMC at any given VMMC site, using a difference-in-differences analysis approach.

The Tunza Network are a social franchise of private practitioners who use with PSI reproductive health products. Tunza practitioners will be trained to offer HIVST kits to their patients. Research evaluation will be limited to safety reporting and analysis of the effect of introducing this method through comparison of before-after time trends in demand for ART referrals at any given Tunza site, using a difference-in-differences analysis approach.

5.5 Health economics

5.5.1 Costing studies

Costing will estimate the societal-level costs of providing HIVST interventions, both from the perspective of the health provider and the user. The MLW-LSHTM team will also collect costs on current MoH HIV prevention, testing and counselling, and treatment services.

The costing study will feed into estimates of cost-effectiveness, which are to be projected on different time scales and population levels. The first cost-effectiveness study will be a short-term, trial-based evaluation using costs and impacts directly measured within the scope of PSI HIVST distribution. The second study will be model-based and explore the long-term population costs and effects at scale using mathematical modelling.

Costing data will be collected initially within the CBDA evaluation villages, but will be expanded to all locations where PSI will be distributing HIVST kits through CBDA, peer, Tunza, and VMMC mobiliser models.

5.5.2 Study period

The costing study will run in parallel with the distribution of HIVST kits by PSI. During this period, MLW-LSHTM will collect programmatic expenditure data from PSI on a monthly basis. Data on user costs of accessing HIVST and HTC services will be gathered through the extended baseline questionnaire administered to adults living in Evaluation Villages.

Data from relevant HIV prevention, testing, and care facilities will be extracted throughout the project period, with data from ART clinics obtained from interview of staff and analysis of primary care clinic and District expenditure records, with permission of MOH and DHOs.

5.5.3 Study population and study size

Full financial and economic costs from the providers' perspective will be collected through PSI and MoH facilities. User costs of accessing existing and new forms of HIV testing and

linkage to care will be gathered using the extended baseline questionnaire, which will be assigned to a random sample of ~1000 enumeration participants.

5.5.4 Data Collection

Costing tools will be used in conjunction with service-related financial and activity reports in order to determine the unit costs of providing HTC and subsequent HIV care. Obtaining costs from MoH will require permission from MoH and District Health Officers (DHO). MLW-LSHTM will also carry out detailed micro-costing, including time and motion studies, to clinics assigned to the intervention and control arms of the impact evaluation. This is important in order to identify instances of reduced crowding in ART clinics due to HIVST decentralisation.

Full PSI costs for HIVST distribution will be derived from programme expenditure reports, while user costs will be collected through questions asked on service utilisation costs in the extended baseline questionnaire.

5.5.5 Data analysis

Gathered costing data will be used to conduct an economic evaluation, using decision-analytic modelling, to compare the costs of the different HIVST models to current MoH HTC models. Key outcomes include the incremental cost per Disability Adjusted Life-Year (DALY) averted, which will allow the cost-effectiveness of HIVST and linkage to care models to be determined.
Additionally, a model of scale-up costs will be developed that takes into consideration budgetary constraints. This will include costs from the providers' perspective, but also changes in total societal costs once user costs have been taken into account.

5.6 Outcome evaluation

5.6.1 Data Capture

Four data collection channels will be employed for the impact evaluation:

1. Pre- and post-intervention household surveys
2. CBDA registers and forms
3. ART clinic registers and forms, and
4. Harms monitoring records.

Data will be collected using tablet computers and paper-based forms.

CBDA logbooks and forms

Process data on HIVST distribution by CBDAs will be captured using HIVST logbooks (date, name, village and number of test-kits taken), returned kits, self-completed questionnaires (SCQ), and self-referral cards for ART clinics.

The SCQ will include questions about the self-read HIVST result, satisfaction, coercion, and HIV testing and ART history. The returned kits will be collected and read against the SCQ by field supervisors before disposal. This will allow the study team to conduct confirmatory readings of HIVST results and provide an ongoing measure of accuracy. CBDAs will also use registers to track the age, sex and HIV and ART history of participants and the nature of support received for HIVST.

ART registers and forms

To monitor the number of referrals, HIV diagnoses and ART initiations, the study will extract routine facility records and, if applicable, self-referral cards from ART clinics serving the evaluation villages.

Harms monitoring records
Identified community leaders will provide weekly reports of deaths and any known episodes of domestic violence. CBDAs will then investigate any possible links to HIVST.

Data capture forms and questionnaires are shown in the Appendices

5.6.2 Data security

Hard copies of data and study documentation will be kept in locked offices, and long term storage will be in locked cupboards in a locked repository.

Electronic copies of data will be saved in password-protected files. All data will be backed up daily by the MLW Data Office, with offsite back up once weekly. Backup data will be stored in a locked filing cabinet away from the office by the PI.

5.6.3 Quality assurance

Data will be checked for internal inconsistencies during verification and following data entry. Quality assurance protocols will be developed for each stage of the study, detailed as SOPs.

PSI supervisors will carry out periodic spot-checks on CBDAs, with visit at home of recent HIVST participants.

ART clinic data will be extracted by PSI supervisors. MLW data team will check data and raise any queries, and will also visit each ART clinic quarterly.

5.6.4 Outcome evaluation

For the comparison of **coverage of recent / ever HIV testing**, outcomes will be evaluated through household surveys as detailed above.

For evaluation of **ART initiations within study area villages**, maps showing study area boundaries and names of participating villages will be produced and displayed in HCT and ART clinics. ART register completion will be adjusted in collaboration with MoH to allow previous HIVST / home-initiation episodes to be documented in the "Comments" column.

Clinic staff will be asked to ensure that all clients are asked directly if they are attending following HIVST results and that the village of residence is clearly recorded in the ART register. The self-referral cards, which are presented by the participants to the clinic, will contain spaces for ART clinic staff to log confirmatory results, the national ART number for clients entering HIV care, and any other relevant referrals (e.g., VMMC).

PSI CBDA supervisors will extract these data on a monthly basis from each of the 20 ART clinics included in the study. Retrospective data extraction will also be used to provide an indication of pre-intervention ART initiations from the 20 study clinics.

In **Home-Initiation villages**, where participants have the option of requesting home initiation of care, PSI CBDA supervisors will fill out HIV care registration cards and maintain a logbook allowing cross-reference by ART number with the local ART clinic. Total numbers of clients confiding positive HIVST results will be recorded by all CBDAs in post-test logbook recording disclosure and other referral events without name.

5.7 Data management

5.7.1 Quantitative data management

Quantitative data will be captured using electronic devices (Tablets) or onto Optical Character Recognition forms, and entered into a dedicated database (Microsoft Access). Incoming electronic data will be checked on a daily basis for errors, with supplemental training provided to field staff if required. In the case of external manual data, MLW-LSHTM will provide training on data collection and assess quality and accuracy through quarterly (initially monthly) supervisory visits.

All data will be cleaned and analysed using Stata software (Stata Corporation, College Station, Texas, USA). All participants will be assigned a study ID number. Participant names will not be linked except through paper-based recruitment logs, which will be stored in locked cupboards and not entered into electronic form.

5.7.2 Qualitative data management

Qualitative data will be recorded in two forms – observational notes and digital audio recordings – and cross-referenced for accuracy. A backup copy of the audio file will be saved on RedCAP, the MLW data management programme, while another copy will be sent to the transcription and translation team. The audio file will be transcribed verbatim into written chiChewa. Transcriptions and notes will then be translated into English. All data will then be transferred to a qualitative data analysis software package, NVIVO 10 (QSR, Melbourne, Australia) and filed according to document type. Coded data will be transferred to a Microsoft Excel spreadsheet for broader thematic analysis.

5.8 Data analysis

Standard approaches to analysis CRT data will be used. Sample size calculations are detailed in the Statistical Considerations section.

5.8.1 Description of the HIVST and SOC arms in the baseline survey

The characteristics of participants recruited into the baseline survey will be described by arm (HIVST and SOC). Cluster-level factors will be summarised at baseline using the mean, median and range, by intervention arm, based on data from the facility assessment, conducted at baseline.

5.8.2 Description of the HIVST and SOC arms in the follow-up survey

The characteristics of participants recruited into the follow-up survey, by arm (HIVST and SOC) will be described. All characteristics will be compared by arm of the trial to assess for comparability. Any variables for which there is a substantial imbalance will be noted so that final analysis can take this into account. This assessment will not be based on the results of hypothesis tests, and p-values will not be shown.

5.8.3 Missing data

Missing data will be examined for each variable and for each cluster or individual participant. A systematic assessment of missingness will be conducted to ascertain the reason and possible mechanism for missing data by identifying the quantity of missing data and patterns within the data. Missingness will be particularly examined by cluster and between randomised arms to assess for systematic biases. Sensitivity analysis for the primary outcome of recent test for HIV will be carried out – comparing complete case analysis results with those where missing outcome status are re-classified as yes and no.

5.8.4 Outcomes

Overall numbers of ART initiations per 1,000 total adult population will be calculated for each clinic during months 1 to 12, and will be compared between intervention and control arms after adjusted for any major imbalance between the trial arms in factors such as pre-intervention ART initiation rates.

The proportion of residents accepting HIV testing will be estimated both overall and within sex, age and village strata, using population denominators from the post-intervention household prevalence survey. Participant characteristics during different time periods of the study will also be compared.

Estimates of linkage into newly accessed care will be assessed using the referral completion rate. This will compare the number of participants who disclosed positive results to CBDAs during a specific period of time to the number of participants accessing confirmatory testing following HIVST over the same time period.

The number of new HIV-positive cases will be ascertained through re-reading of returned kits and participants sharing results with CBDAs.

5.8.5 Methods

All statistical analyses will be based on methods used for CRTs with a small number of clusters (Campbell, et al. 2012). The analysis for the first randomisation is based on a total of 20 clusters.

Summary measures
For binary outcomes the overall risk, combining data across clusters, and means of cluster-level risk will be reported by intervention arm. For quantitative outcomes, the overall mean and cluster-level means will be reported by intervention arm.

Unadjusted analysis
The analysis will give each cluster equal weight. The overall risk/mean for each cluster will be calculated.

A log transformation (where necessary) will be applied to the risk/rate/mean for each cluster. For binary outcomes where there are clusters with no events, one event will be added to all clusters so that the log transformation can be conducted. The mean and standard deviation of these log risks/rates/means will be used to obtain the geometric mean (GM) and associated 95% CI for each arm of the study.

The risk/mean ratio, 95% confidence interval and p-value is estimated using a t test and the log risks/rates/means by arm, based on 18 degrees of freedom.

Adjusted analysis
Factors for adjustment will be determined as stated above.

Depending on the outcome to be analysed, logistic/linear regression will be used to adjust for confounders at the individual level and cluster level, adopting a two-stage approach.

The regression model will include terms for the individual level adjustment factors, but not study arm. For each cluster the fitted model will be used to obtain the ratio of observed to expected (O/E) events, and a log transformation will be applied to this ratio, where appropriate. A t test of the log (O/E) by arm will be used to estimate the risk ratio, 95% CI and p-value. If adjustment for cluster level factors is considered necessary, this will be conducted at the second stage using linear regression of the log (O/E) on arm and cluster level factors, with appropriate adjustment for the degrees of freedom.

Stratified (subgroup) analyses

Stratified analyses (sub-group) for the primary outcome will be pre-specified before the end of data collection,

Stratified analyses based on effect modification by cluster- or individual-level covariates will be analysed as follows: the effect of the intervention will be estimated for each strata. For individual-level covariates this will be accompanied with p-values for effect modification using the approach by Cheung et al (Cheung, et al. 2018).

6. Adverse Event Reporting and Management

6.1. HIVST

HIV testing and counselling including HIVST is well established, and known to have a high level of safety and favourable risk: benefit ratio. However, harmful reactions can occur. For the purposes of this trial, we will focus on capture of the following **Serious Adverse Events.**

- Death or hospitalisation due to self-inflicted injuries within 30 days of a positive HIVST results
- Death or hospitalisation resulting from violent assault by others (intimate partner violence, assault by family members, assault by community members) within 30 days of a positive HIVST result

Deaths and hospitalisations will be captured through the Social Harms System established in each cluster. The PSI Supervisor will interview the client and relatives to establish relatedness where possible.

6.2. Institutional responsibilities

SAEs will be reported immediately to the PI or MLW Coordinator. All other adverse events will be logged and reported through regular follow-up reports.

As this is a public-health scale-up evaluation, following an intervention trial that showed low risk of harm from HIVST (no suicides from 27,000 HIVST episodes), expected SAEs will be reported through 6-monthly progress reports that will report on safety as well as other important process indicators and will be sent to the Technical Advisory Group members and local and international collaborators.

12 monthly reports with full listings of SAEs will be submitted to Ethics Review Boards at the time of annual reporting.

6.3. Reporting procedures

SAE forms will be completed by the MLW Trial Coordinator and responsible CBDA Supervisor and reported to the PI. The PI will check the form, make changes as necessary.

SAEs will be evaluated for seriousness, and likely relatedness by the PI.

7. Statistical considerations and sample size

7.1. Precision for the pilot accuracy study

Figure 9. Sample size calculation – tested for HIV in last 12 months

The table below summarises precision obtained from the pilot accuracy study for a range of scenarios around participation in HIVST

# people conducting self-tests	Proportion results concordant with confirmatory tests	
	95%	**98%**
114[1]	94.7% (89.0%, 98.0%)	98.2% (93.8%, 99.8%)
127[2]	95.3% (90.0%, 98.2%)	
200	95.0% (91.0%, 97.6%)	98.0% (95.0%, 99.5%)
250	94.8% (91.3%, 97.2%)	98.0% (95.4%, 99.3%)
278[3]	95.0% (91.7%, 97.2%)	97.8% (95.4%, 99.2%)

[1] Assumes 228 eligible individuals identified, with 50% participation in self-testing

[2] Minimum sample size that allows an accuracy of 95% to have a 95% CI that is above 90%

[3] Assumes 308 eligible individuals identified, with 80% participation in self-testing

Shaded area indicates the range of scenarios considered most likely

7.2. CRT sample size calculations

This trial has one primary and one secondary outcome, with a number of other analyses to be specified in the Statistical Analysis Plan. The sample size considerations here relate to the main Primary Outcome (comparison between arms of recent HIV testing).

A survey sample of 250 to 500 adults per cluster will provide sufficient power for a two sample comparison of unmatched proportions for HTC coverage was performed across the intervention and control arms to determine the number of clusters per arm.

The cluster size is based on the typical size of a rural village (250-500 people) from previous experience in Malawi. Using 2010 DHS data, baseline rates for individuals tested in the last 12 months is estimated at 25% to 40%, with a 45% to 60% predicted effect size in the intervention arm compared to the control arm. Baseline coverage for individuals who have ever tested is estimated at 42% to 60% with predicted effect size 30%-45%.

Figures 10 and 11 contain a table of scenarios for each of the outlined assumptions. To detect a 50% increase in rate of people testing in the past 12 months and a 45% increase in the percentage of people who have ever tested in the intervention villages, there should be approximately 8 clusters per arm and approximately 4,000 participants total. This study will aim to reach 10 clusters per arm and 5,000 participants to provide contingency for a lower than anticipated effect size.

Figure 10. Sample size calculation – tested for HIV in last 12 months

1-type l	Power	Baseline testing	Effect size	Interven-tion testing	Cluster size	k	Number of clusters	Total partici-pants
0.95	0.8	0.35	0.6	0.56	250	0.25	6.19	3094.21
0.95	0.8	0.3	0.6	0.48	250	0.25	6.30	3148.20
0.95	0.8	0.25	0.6	0.4	250	0.25	6.45	3223.78
0.95	0.8	0.35	0.55	0.5425	250	0.25	6.92	3460.38
0.95	0.8	0.3	0.55	0.465	250	0.25	7.05	3523.39
0.95	0.8	0.25	0.55	0.3875	250	0.25	7.22	3611.61
0.95	0.8	0.35	0.5	0.525	250	0.25	7.87	3933.04
0.95	0.8	0.3	0.5	0.45	250	0.25	8.02	4007.80
0.95	0.8	0.25	0.5	0.375	250	0.25	8.22	4112.45
0.95	0.8	0.35	0.45	0.5075	250	0.25	9.12	4560.03
0.95	0.8	0.3	0.45	0.435	250	0.25	9.30	4650.47
0.95	0.8	0.25	0.45	0.3625	250	0.25	9.55	4777.08

Figure 11. Sample size calculation – ever tested for HIV

1-type l	Power	Baseline testing	Effect size	Interven-tion testing	Cluster size	k	Number of clusters	Total partici-pants
0.95	0.8	0.6	0.45	0.87	250	0.25	8.67	4333.93
0.95	0.8	0.5	0.45	0.725	250	0.25	8.79	4397.24
0.95	0.8	0.42	0.45	0.609	250	0.25	8.94	4469.59
0.95	0.8	0.6	0.4	0.84	250	0.25	10.28	5139.67
0.95	0.8	0.5	0.4	0.7	250	0.25	10.44	5218.16
0.95	0.8	0.42	0.4	0.588	250	0.25	10.62	5307.86
0.95	0.8	0.6	0.35	0.81	250	0.25	12.58	6291.61
0.95	0.8	0.5	0.35	0.675	250	0.25	12.78	6391.99
0.95	0.8	0.42	0.35	0.567	250	0.25	13.01	6506.71
0.95	0.8	0.6	0.3	0.78	250	0.25	16.06	8030.49
0.95	0.8	0.5	0.3	0.65	250	0.25	16.33	8164.21
0.95	0.8	0.42	0.3	0.546	250	0.25	16.63	8317.04

Extended individual questionnaire and post-intervention household survey

The sample size for the extended individual questionnaire is based on the minimum sample size needed for the DCE to measure choice probabilities with a high level of accuracy. Though sample size calculations for DCEs have not been formalised in the same manner as trials, conventional sample sizes tend to be around 200 participants per population strata, though new efficient experimental designs do allow for smaller samples.

The study will use five strata in total, generating a sample size of 1,000 participants. Strata of interest include low and high HIV risk, young (16 to 30 years) and old (31 years or more), male and female, self-identified HIV positive and negative, and Socio-Economic Status (SES) quintiles.

8. Results presentation and dissemination

Descriptive and inferential findings will be presented through tables and histograms, line graphs and other figures, where relevant.

The results of this research will be used to guide the introduction of self-testing into community-based HTC models and the formation of national and international policies around HIVST. Results will be disseminated to the MoH HIV Unit, COMREC and UNITAID. A report on the study will be produced and disseminated to COMREC, the College of Medicine (COM) Library, the Health Sciences Research Committee and the University Research and Publication Committee. Findings will also be distributed internationally to global health policy makers, nationally to the Malawian government, and regionally to District and Council Health Offices. Presentations will be given at the COMREC research dissemination day and at MLW research-in-progress meetings. Copies of peer-reviewed publications from the research will be submitted to COM, MLW, and LSHTM.

In terms of public engagement, the MLW-LSHTM team will work with the MLW Science Communication team to disseminate the project results and raise the profile of HIVST in Malawi. MLW actively engages with both urban and rural communities, and has already hosted a range of programmes including science cafes, radio projects, and mobile exhibitions about HIVST. These mediums will be employed to educate the general public about the UNITAID project and the results.

9. Ethical considerations

9.1 Confidentiality

Participants will not have their names used during any stage of data collection except in recruitment logbooks and will be given a unique identifier. Hard copies of questionnaires and transcripts will be kept in locked cupboards in a secure location in MLW and electronic transcripts will be password protected on a computer accessible only to authorised staff members.

9.2. Informed consent

Informed consent will be taken for participation in certain parts of the study. If the sub-study requires that participants give written consent, the investigator will first provide the potential subject with an explanation of the study as well as an information sheet with study details. The investigator will answer any questions raised by the potential participant and allow them sufficient time to come to a decision. Participants will then be required to give consent. In cases where written consent is required and the participant is illiterate, they will be asked to give verbal consent plus a thumb print. Parental consent will be required if participants are 16 or 17 years old.

Figure 12. Consent requirements for each research activity

Method	Consent Requirements
Cognitive interviews	Written
Key Informant inerviews	Written
FGD	Written
IDI	Written
HIVST + HTC for pilot accuracy studies	Written
Baseline household survey	Verbal
Extended individual questionnaire	Written
Post intervention household survey	Written
PSI-led HIVST distribution	Request waiver of informed consent; leaflets provided in lieu of participant information sheets
Process evaluation	N/A
DCE	Written
Costing study	N/A

9.3. HTC and HIVST

All individuals selecting to self-test will be offered pre- and post-test information and referral to the most convenient clinic offering ART services. Participants will also be given the opportunity to discuss any fears about the process or results prior to testing and to disclose their status and receive advice and support for post-test services.

Participants are not required to disclose the results of HIVST to the distribution agent, but such will be encouraged so that they can receive results-based, post-test information. The only exception is during the pilot accuracy study, where self-testing will need to be disclosed in order to verify the accuracy of HIVST results against confirmatory results.

All disclosed HIV status results will remain confidential.

9.4. Compensation for participation

Study participants will be compensated for their time away from income-earning activities, but this will be packaged as compensation rather than payment. This will include refreshments, refund of any transport costs incurred. For those exposed to the HIVST intervention, the decision to self-test or not will not influence the amount of compensation.

Compensation will be as follows:

- MWK 1000 per household for participation in the Household Surveys
- MWK 1000 for individuals participating in FGDs, IDIs, cognitive interviews and pilot accuracy studies

10. Constraints and limitations

10.1. Risk mitigation

Social harms monitoring will be conducted by MLW-LSHTM and PSI throughout the HIVST distribution period to respond to incidences of coercion, GBV, and other potential unintended consequences from self-testing. Systems for tracking social harms include a community-based reporting network using community stakeholders and leaders and hotline for HIVST participants to call and report adverse events. Tracking of social harms will then enable MLW-LSHTM to assess and mitigate adverse events arising from HIVST.

10.2. Data quality

MLW-LSHTM has considerable expertise in supporting all aspects of quality data management in Malawi. Standard Operating Procedures (SOP) will be used on study design, data collection instruments and data analysis procedures, with routine data quality audits conducted for quality assurance purposes. PSI and MLW-LSHTM have also invested in electronic data collection, using open source software and computer tablets. This approach improves data collection efficiency and reduces traditional weaknesses associated with data collection such as completeness, consistency, and timeliness. Additionally, MLW has substantial experience with bridging any gaps in MoH records and project data requirements, using extraction of registers onto Optic Character Recognition forms.

The Research Governance unit in MLW will conduct periodic (usually annual) internal audits to ensure that all documentation and data capture is within acceptable international standards. Should PSI Malawi data be found to be not compliant with SOPs or fail a data quality audit, they will be required to revise their practices with close supervision from external technical staff, i.e., Regional Researchers and Health Area Research Advisors.

10.3. Governance

HIV STAR will form a Technical Advisory Group (TAG) to review data and provide expert opinion on whether a product should be pre-qualified, and to support post-market surveillance reports and supervision when products enter the market place.

HIV STAR has the support of key officials in the Government of Malawi. The MoH has collaborated in a number of HIVST projects to date and supported publications and presentations from projects hosted by MLW. The Director of the Department of HIV and AIDS of the MoH, is a collaborator with the MLW HIVST project and has provided a letter of support for the UNITAID project.

11. Capacity building and training

This research will contribute to qualitative and quantitative data capacity at the College of Medicine both in terms of establishing a resource base of qualified and trained researchers

to conduct qualitative and quantitative fieldwork and a system for accurate and timely transcription and translation services and data management.

Data and field staff employed on the project will be trained in both qualitative and quantitative techniques, in Good Clinical Practice, and on the protocol, and will be uniquely placed to understand the complementarity of triangulation between quantitative and qualitative methods.

12. HIV STAR Malawi Budget

13. Budget justification

14. HIV STAR-M Work Plan

Activities	Lead	Group	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Y2 Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug
A. CRT																							
Partner with MoH to select evaluation clinics and villages	PI/LC/PM	MLW/PSI		■																			
Meet with community leaders and clinics to explain study	PM	PSI/MLW		■																			
Develop database for quantitative data	DM/PI	MLW		■																			
Identify and obtain GPS coordinates for village and household boundaries	PM/PI	PSI/MLW		■																			
Train field/data team on tools and SOPs	PI/DM/PM	MLW/PSI			■																		
Train ART clinic staff on tools and SOPs					■																		
Train CBDAs on tools and SOPs	PI/PM	MLW/PSI						■															
Randomly assign intervention to evaluation villages	PI/LC	MLW						■															
Collect and analyse data for baseline household survey																							
Pilot baseline survey and revise based on feedback	PI/PM	MLW/PSI			■																		
Enumerate households and randomly recruit participants for extended survey	PM/PI	PSI/MLW			■	■																	
Pilot extended baseline questionnaire and revise based on feedback	PI/PM	PSI/MLW				■																	
Conduct extended baseline questionnaire	PM/PI	PSI/MLW				■	■																
Conduct quality and accuracy checks on incoming electronic data	PI/DM	MLW			■	■	■																
Clean quantitative data	DM/PI	MLW			■	■	■																
Conduct preliminary analysis of quantitative data	PI/LC/MN	MLW/LSHTM					■	■															
Generate preliminary report on baseline findings	PI/LC	MLW					■	■															
Conduct in-depth analysis of quantitative data	PI/LC/MN	MLW/LSHTM						■	■	■	■	■	■	■	■								
Generate in-depth report on baseline findings	PI/LC	MLW												■	■								
Collect and analyse data for interim household survey																							
Pilot extended interim household survey and revise based on feedback	PI/PM	PSI/MLW												■									
Conduct interim household survey	PM/PI	PSI/MLW													■								
Conduct quality and accuracy checks on incoming electronic data	PI/DM	MLW													■								
Clean quantitative data	DM/PI	MLW													■								
Conduct preliminary analysis of quantitative data	PI/LC/MN	MLW/LSHTM														■	■						
Generate preliminary report on interim findings	PI/LC	MLW														■	■						

Conduct in-depth analysis of quantitative data	PI/LC/MN	MLW/LSHTM	
Generate in-depth report on interim findings	PI/LC	MLW	
Collect and analyse data from CBDAs and ART clinics			
Pilot CBDA tools in intervention villages and revise based on feedback	PI/PM	MLW/PSI	
Collect SCQs and HIVST registers and kits from CBDAs in intervention villages	PI/PM/CC	MLW/PSI	
Collect harms monitoring records from community leaders in intervention villages	PI/PM/CC	MLW/PSI	
Collect patient registers and referral forms from ART clinics	PI/PM/CC	MLW/PSI	
Enter paper-based data into electronic files	DM	MLW	
Conduct quality and accuracy checks on incoming electronic data	PI/DM	MLW	
Clean quantitative data	DM/PI	MLW	
Conduct preliminary analysis of quantitative data	PI/LC/MN	MLW/LSHTM	
Generate preliminary report on impact evaluation findings	PI/LC	MLW	
Conduct in-depth analysis of quantitative data	PI/LC/MN	MLW/LSHTM	
Generate in-depth report on impact evaluation findings	PI/LC	MLW	
B. COGNITIVE INTERVIEWS			
Partner with MoH to select health facilities	PI/LC	MLW	
Meet with clinic staff and community leaders to ensure project buy-in	PI/LC	MLW	
Train SS-RA on tools and SOPs	PI/ND	MLW-SS	
Pilot tools and revise based on feedback	PI/SS-RA	MLW-SS	
Identify and recruit study participants	SS-RA/PI	MLW-SS	
Conduct cognitive interviews	SS-RA/PI	MLW-SS	
Conduct quality checks on collected data	PI/TT	MLW-SS	
Enter paper-based data into electronic files	DM/TT	MLW-SS	
Conduct ongoing analysis of qualitative data and iteratively revise IFUs	PI/ND/LC	MLW-SS	
Generate report on findings with recommendations on prototype IFUs/IEC materials	PI/ND/LC	MLW-SS	
C. KEY INFORMANT INTERVIEWS			
Conduct document review on HIV policy and regulation	SRA	LSTM	
Identify and recruit HIV policy and regulation stakeholders	SRA/ND	LSTM/MLW-SS	
Conduct KII with HIV policy and regulation stakeholders	SRA	LSTM	
Transcribe interviews into electronic files	TT	LSTM	
Clean and code qualitative data	SRA	LSTM	
Conduct analysis of qualitative data	SRA/ND	LSTM/MLW	

Generate report on findings with recommendations on policy/regulatory actions	SRA/ND	LSTM/MLW-SS												■	■								
D. PILOT STUDY																							
Partner with MoH to select pilot villages	PI/LC	MLW		■																			
Meet with community leaders to ensure project buy-in	PI/LC	MLW		■																			
Train field and data team on tools and SOPs	PI	MLW		■																			
Develop database for quantitative data	DM/PI	MLW		■																			
Identify and obtain GPS coordinates for village and househould boundaries	FM/PI	MLW		■																			
Collect and analyse data for mapping exercises																							
Conduct transect walks and mapping exercises in pilot villages	SS-RA/PI	MLW-SS			■																		
Enter paper-based data into electronic files	TT	MLW-SS			■																		
Conduct analysis of qualitative data	PI/ND/LC	MLW-SS			■																		
Develop pilot social harms reporting system	PI/ND/LC	MLW-SS			■																		
Collect and analyse data for feasibility, acceptability and accuracy study																							
Identify and recruit households for accuracy study	FM/PI	MLW			■																		
Identify and recruit peer organisations for accuracy study and FGDs	FM/PI/SS-RA	MLW-SS			■																		
Identify and recruit household members for IDIs	FM/PI/SS-RA	MLW-SS				■	■																
Pilot tools and revise based on feedback	PI/FM/SS-RA	MLW-SS			■																		
Conduct HTC/HIVST for accuracy study	FM/PI	MLW			■	■	■																
Conduct FGDs with peer groups	SS-RA/PI	MLW-SS			■																		
Conduct IDIs with adults from randomly selected households	SS-RA/PI	MLW-SS				■	■																
Conduct quality and accuracy checks on collected data	PI/DM	MLW			■	■	■																
Enter paper-based data into electronic files	DM	MLW			■	■	■																
Clean quantitative data	DM/PI	MLW			■	■	■																
Transcribe and translate qualitative data	TT	MLW-SS			■	■	■																
Clean and code qualitative data	SSA	MLW-SS			■	■	■																
Conduct preliminary analysis of quantitative data	PI/LC/MN	MLW/LSHTM					■	■															
Conduct ongoing analysis of qualitative data	PI/ND/LC	MLW-SS					■	■															
Generate preliminary report on pilot findings	PI/LC/ND	MLW					■	■															
Conduct in-depth analysis of quantitative data	PI/LC/MN	MLW/LSHTM												■	■								
Conduct in-depth analysis of qualitative data	SSA/ND	MLW-SS												■	■								
Generate in-depth report on pilot indings	PI/LC/ND	MLW												■	■								
E. PROCESS EVALUATION																							
Agree on key indicators and M&E data to be collected by PSI	PI/DM/MEO	MLW/PSI			■	■																	

Assist PSI in developing M&E data collection tools and database	PI/DM/MEO	MLW/PSI	
Extract M&E data from PSI	DM/MEO	MLW/PSI	
Conduct preliminary analysis of M&E data	PI/LC	MLW	
Generate preliminary report on findings	PI/LC	MLW	
Conduct in-depth analysis of M&E data	PI/LC	MLW	
Generate in-depth report on findings	PI/LC	MLW	
F. DCE			
Collect and analyse data for DCE formative research (embedded in pilot study)			
Conduct DCE FGDs	RA-SS/PI	MLW-SS	
Develop scenarios and illustrations based on FGDs	FTP/PI	LSHTM/MLW	
Conduct DCE IDIs	RA-SS/PI	MLW-SS	
Conduct preliminary analysis of qualitative data	SRA/ERA	LSHTM/MLW	
Generate preliminary report on DCE findings	SRA/ERA	LSHTM/MLW	
Collect and analyse data for DCE (embedded in baseline household survey)			
Develop DCE survey based on qualitative research	ERA/SRA	MLW/LSHTM	
Pilot DCE survey and revise based on feedback	PM/PI	PSI/MLW	
Conduct DCE survey	PM/PI	PSI/MLW	
Conduct preliminary analysis of DCE data	SRA/ERA	LSHTM/MLW	
Generate preliminary report on DCE findings	SRA/ERA	LSHTM/MLW	
Conduct in-depth analysis of DCE data	SRA/ERA	LSHTM/MLW	
Generate in-depth report on DCE findings	SRA/ERA	LSHTM/MLW	
G. COSTING STUDY			
Meet with MoH to gain permission to access financial data	ERA	MLW	
Develop database for quantitative data	DM/ERA	MLW	
Train data team on tools and SOPs	PI/ERA/DM	MLW	
Collect user HTC cost data (as part of baseline household survey)	ERA/PI	MLW	
Collect provider cost data (as part of ART data collection)	ERA/PI	MLW	
Collect user HIVST cost data (as part of interim household survey)	ERA/PI	MLW	
Collect PSI HIVST financial data	ERA/PI	MLW	
Collect MoH HTC financial data	ERA/PI	MLW	
Enter paper-based data into electronic files	DM	MLW	
Conduct quality and accuracy checks on electronic data	PI/DM/ERA	MLW	
Clean quantitative data	DM/PI/ERA	MLW	
Conduct preliminary analysis of cost data	SRA/ERA	LSHTM/MLW	

Generate preliminary report on findings	SRA/ERA	LSHTM/MLW																						
Conduct in-depth analysis of cost data	SRA/ERA	LSHTM/MLW																						
Generate in-depth report on findings	SRA/ERA	LSHTM/MLW																						

References

Angotti, N., A. Bula, L. Gaydosh, E.Z. Kimchi, R.L. Thornton, and S.E. Yeatman. 2009. "Increasing the Acceptability of HIV Counseling and Testing with Three C's: Convenience, Confidentiality and Credibility." *Social Science & Medicine* .

Baral, S., A. Scheibe, P. Sullivan, G. Trapence, A. Lambert, L.G. Bekker, and C. Beyer. 2009. "HIV Prevalence, Risks for HIV Infection, and Human Rights among Men who have Sex with Men in Malawi, Namibia and Botswana." *PLoS One*.

Cambiano, V., S.N. Mavedzenge, and A. Phillips. 2014. "Modelling the Potential Population Impact and Cost-Effectiveness of Self-Testing for HIV: Evaluation of Data Requirements." *AIDS and Behaviour*.

Campbell, MK, G Piaggo, DR Elbourne, DG Altman, and C Group. 2012. *Consort 2010 statement: extension to cluster randomised trials*. BMJ, 345.

Cheung, YB, D Jeffries, A Thomson, and P Milligan. 2018. *A simple approach to test for interaction ebtween intervention an an individual-level variable in community randomized trials*. Trop Med Int Health.

Choko, A., P. MacPherson, E. Webb, B. Willey, H. Feasy, R. Sambakunsi, A. Mdolo, et al. 2015. *Uptake, Accuracy, Safety, and Linkage into Care over Two Years of Promoting Annual Self-Testing for HIV in Blantyre, Malawi: A Community-Based Prospective Study*. PLoS.

Corbett, E.L. ISRCTN02004005. London: ISRCTN Registry; 2012. 10.1186/ISRCTN02004005. "Intensified HIV/TB Prevention Linking Home-Based HIV Testing, including the Option of Self-Testing with HIV CARE."

Desmond, Nicola. ID 099051/Z/12/Z. "The Social Impact of HIV Self-Testing: Reconstructing Knowledge and Re-framing Risks Associated with HIV Prevention."

Frith, L. 2007. "HIV Self-Testing: A Time to Revise Current Policy." *The Lancet*.

Gaydos, C.A., Y.H. Hsieh, A. Bura, M. Barnes, H. Won, M. Jett-Goheen, N. Arora, P. Agreda, and R. Rothman. 2009. "Can We Ever Expect to Have Individuals Perform Their Own HIV Rapid Tests?" *Infectious Diseases Society of America 47th Annual Meeting*. Philadelphia.

Govindasamy, D., N. Ford, and K. Kranzer. 2012. "Risk Factors, Barriers and Facilitators for Linkage to Antiretroviral Therapy Care: A Systematic Review." *AIDS*.

MacPherson, P, E.L. Corbett, S. Makombe, J. van Oosterhout, E. Manda, A. Choko, D. Thindwa, S.B. Squire, G. Mann, and D. Lalloo. 2012. "Determinants and Consequences of Failure of Linkage to Antiretroviral Therapy at Primary Care Level in Blantyre, Malawi: A Prospective Cohort Study." *PLoS One*.

MacPherson, P., D. Lalloo, E. Webb, H. Maheswaran, A. Choko, S. Makombe, A. Butterworth, et al. 2014. "Effects of Optional Home Initiation of HIV Care Following HIV Self-Testing on Antiretroviral Therapy Initation Among Adults in Malawi." *Journal of the American Medical Association*.

Ministry of Health Kenya. 2009. "Guidelines for HIV Counselling and Testing."

Morin, S.F., G. Khumalo-Sakutukwa , E.D. Chalebois, J. Routh, K. Fritz, and T. Lane. 2006. "Removing Barriers to Knowing HIV Status: Same-Day Mobile HIV Testing in Zimbabwe." *Journal of Acquired Immune Deficiency Syndromes*.

Napierala Mavedzenge, S., and E.L. Corbett. 2009. *HIV Self-Testing among Health Workers: Review and Recommendations*. Geneva: HIV Department, World Health Organisation.

National Statistical Office and ICF Macro. 2011. *Malawi Demographic and Health Survey 2010*. Zomba, Malawi and Calverton, Maryland: NSO and ICF Macro.

Pant-Pai, N., and M.B. Klein. 2008. "Are We Ready for Home-Based Self-Testing for HIV?" *Future HIV Therapy*.

Project Masiluleke. 2010. *Project Masiluleke: Utilising Mobile Technology and HIV Self-Testing in South Africa*. iTREAT. www.iTREAT.com.

2010. *Project Masiluleke: Utilising Mobile Technology and HIV Self-Testing in South Africa*. iTREAT. www.iTREAT.com.

Spielberg, F., R.O. Levine, and M. Weaver. 2004. "Self-Testing for HIV: A New Option for HIV Prevention?" *The Lancet Infectious Diseases*.

Spielberg, F., S. Camp, and R. Ramachandra. 2003. "HIV Home Testing - Can it Work?" *National HIV Prevention Conference*. Atlanta.

UNAIDS. 2014. *Global AIDS Response Progress Report - Malawi Progress Report for 2013*. UNAIDS.

Weinreb, A.A., and G. Stecklov. 2009. "Social Inequality and HIV Testing: Comparing Home-Based and Clinic-Based Testing in Rural Malawi." *Demographic Research* .

Wirtz, AL, G Trapence, V Gama, D Kamba, R Chalera, L Klein, R Kumwenda, T Chikoko, M Mangochi, and S Baral. 2014. "Final Report to UN Joint Team on HIV and AIDS in Malawi: HIV Prevalence and Sociobehavioral Characteristics among Men who have Sex with Men across Seven Sites in Malawi." Johns Hopkins University.

Wright, E.E, and I.T. Katz. 2006. "Home Testing for HIV." *New England Journal of Medicine*.

Addendum to COMREC submission

Study requirements

Requirements	Category	Item
1. Personnel	Core	Country research manager, admin offer/bookkeeper, administrator, driver*
	Field management	Field manager*
	Data management	Data manager, data collector, data clerk
	Quantitative/economics research	Quantitative research assistant, economics research fellow
	Qualitative research	Social scientist, assistant social scientist, translator/transcriber assistant
2. Training	Good Clinical Practice training (by COM prior to research implementation)	Country research manager, field manager*, data manager, data collector, data clerk, quantitative research assistant, economics research fellow
	Data management (by research coordinator and data manager prior to data collection)	Field manager*, data manager, data collector, data clerk, quantitative research assistant, economics research fellow, social scientist, assistant social scientist, translator/ transcriber assistant
	Protocol (by research coordinator prior to sub-study implementation)	Field manager*, data manager, data collector, data clerk, quantitative research assistant, economics research fellow, social scientist, assistant social scientist, translator/ transcriber assistant PSI: PSI lead, research and field staff, CBDAs MoH: ART facility staff
3. Data collection	Formative research and CRT	Paper-based forms, electronic tablets, audio recorded HIVST kits
4. Transport	Transport to and from research sites	

Forms and Tools Guide

Form No.	Type	Form Name
PS01A	Information Sheet	Participant Information Sheet, Cognitive Interviews
PS01B	Consent Form	Consent Form, Cognitive Interviews
PS101	Qualitative	Cognitive Interview Guide
PS102	Tool	Prototype User Instructions
PS02A	Information Sheet	Participant Information Sheet, Policy and Regulation KII
PS02B	Consent Form	Policy and Regulation KII Consent Form
PS201	Qualitative	Policy and Regulation KII Guide
PS03A	Information Sheet	Participant Information Sheet, Acceptability/Feasibility and Accuracy
PS03B	Consent Form	Consent Form, FGD
PS03C	Consent Form	Consent Form, IDI + Formative DCE
PS03D	Consent Form	Consent Form, HIV Testing
PS301	Qualitative	Community Peer Group FGD Guide
PS302A	Qualitative	Random Household Adult IDI Guide - Individual
PS302B	Qualitative	Random Household Adult IDI Guide - Couple
PS303A	Quantitative	Demographic Questionnaire
PS303B	Quantitative	Self-Completed Test Results Form
PS303C	Quantitative	Exit Questionnaire - Individual
PS303D	Quantitative	Exit Questionnaire - Couple
PS04A	Information Sheet	Participant Information Sheet, Extended Baseline Questionnaire
PS04B	Consent Form	Consent Form, Extended Baseline Questionnaire
PS401A	Quantitative	Baseline HH Survey
PS401B	Quantitative	Baseline HH Survey – Brief Individual Questionnaire
PS402A	Quantitative	Extended Individual Questionnaire
PS501	Quantitative	CBDA Pre-Test Register
PS502	Quantitative	CBDA Post-Test Register
PS503	Quantitative	Self-Completed Questionnaire
PS504	Quantitative	Self-Referral Card